3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Influenza, Human
13
Neoplasms
6
Colorectal Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Recurrence
2
Pancreatic Neoplasms
2
Neuroblastoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Leukemia
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Virus Diseases
1
Vaccine-Preventable Diseases
1
Vaccination Hesitancy
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Patient Acceptance of Health Care
1
Ovarian Neoplasms
1
Osteosarcoma
1
Interventions
Rituximab
99
Cyclophosphamide
63
fludarabine phosphate
54
Peripheral Blood Stem Cell Transplantation
52
Mycophenolic Acid
33
Bortezomib
33
Whole-Body Irradiation
32
ibrutinib
29
Dexamethasone
27
Tacrolimus
25
Cyclosporine
25
Etoposide
22
Busulfan
22
Melphalan
20
Filgrastim
20
Methotrexate
18
Lenalidomide
18
Antilymphocyte Serum
18
Radiotherapy
16
zanubrutinib
14
Bendamustine Hydrochloride
14
Sirolimus
13
Calcium Dobesilate
11
Everolimus
10
venetoclax
9
ibritumomab tiuxetan
9
Prednisone
9
Cyclosporins
9
idelalisib
8
Indium
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Waldenstrom Macroglobulinemia
×
Influenza Vaccines
×
Clear all
NCT02566265
2019-01-30
SHIVERING 2
Yale University
Phase 2
Completed
122 enrolled
10 charts